What Fate Therapeutics Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 2 | 6 |
| Total trades | 2 | 13 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 676,664 |
| Disposed | 82,747 | 153,062 |
| Net activity | −82,747 | +523,602 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Valamehr Bahram | President and CEO | Aug 04 | Open-market sale · S | −43,947 | $2.46 | −$108K | 591,815 |
| Tahl Cindy | See Remarks | Aug 04 | Open-market sale · S | −38,800 | $2.46 | −$95.4K | 589,355 |
| Valamehr Bahram | President and CEO | May 20 | Open-market sale · S | −28,946 | $1.88 | −$54.5K | 635,762 |
| Tahl Cindy | See Remarks | May 20 | Open-market sale · S | −25,590 | $1.88 | −$48.1K | 628,155 |
| Tahl Cindy | See Remarks | May 06 | Exercise / conversion · M | +44,444 | $1.05 | +$46.7K | 653,745 |
| Tahl Cindy | See Remarks | May 06 | Exercise / conversion · M | +122,220 | $1.32 | +$161K | 609,301 |
| Rastetter William H | Director | May 05 | Exercise / conversion · M | +25,000 | $1.69 | +$42.3K | 36,331 |
| Epstein Robert S | Director | May 05 | Exercise / conversion · M | +25,000 | $1.69 | +$42.3K | 36,331 |
| Adawi Kamal | Chief Financial Officer | Jan 15 | Grant / award · A | +25,000 | — | — | 100,000 |
| Valamehr Bahram | President and CEO | Jan 15 | Grant / award · A | +335,000 | — | — | 664,708 |
| Tahl Cindy | See Remarks | Jan 15 | Grant / award · A | +100,000 | — | — | 487,081 |
| Valamehr Bahram | President and CEO | Jan 09 | Open-market sale · S | −5,190 | $1.07 | −$5.56K | 329,708 |
| Tahl Cindy | See Remarks | Jan 09 | Open-market sale · S | −10,589 | $1.06 | −$11.3K | 387,081 |
| Adawi Kamal | Chief Financial Officer | Oct 20 | Grant / award · A | +75,000 | — | — | 75,000 |
| Valamehr Bahram | President and CEO | Aug 04 | Open-market sale · S | −14,466 | $1.06 | −$15.4K | 334,898 |
| Tahl Cindy | See Remarks | Aug 04 | Open-market sale · S | −9,037 | $1.06 | −$9.57K | 397,670 |
| Bressi Jerome Charles | See Remarks | Jan 15 | Grant / award · A | +65,000 | — | — | 335,203 |
| Tahl Cindy | See Remarks | Jan 15 | Grant / award · A | +70,000 | — | — | 406,707 |
| Bressi Jerome Charles | See Remarks | Jan 10 | Open-market sale · S | −5,980 | $1.55 | −$9.27K | 270,203 |
| Valamehr Bahram | President and CEO | Jan 10 | Open-market sale · S | −8,705 | $1.54 | −$13.4K | 349,364 |
Loading...
